IGF-I has been shown to modulate inflammatory pathways and reduce the pathological effects of TNF-α, with treatments like Cerebrolysin demonstrating benefits in AD patients by increasing IGF-I levels and mitigating inflammation [116,117]. This evidence concerns the gene IGF1 and Alzheimer disease.